Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Sanofi’s Qfitlia (fitusiran) has been approved by the US Food and Drug Administration (FDA) as the first therapy to treat ...
The U.S. Food and Drug Administration said on Friday that it has approved Sanofi's (SNY) Qfitlia to treat bleeding in patients aged 12 and older with hemophilia A or B, with or without factor VIII ...
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...